L. G. Mitchell, M. Andrew and K. Hanna, “A Prospective Cohort Study Determining the Prevalence of Thrombotic Events in Children with Acute Lymphoblastic Leukemia and a Central Venous Line Who Are Treated with L-Asparaginase: Results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study,” Cancer, Vol. 97, No. 2, 2003, pp. 508-516. http://dx.doi.org/10.1002/cncr.11042

has been cited by the following article:

• TITLE: Effect of Factor V Leiden on Thrombosis in Childhood Leukemia

  AUTHORS: Dilara Fatma Akın, Nejat Akar

  KEYWORDS: Thrombosis; Acute Leukemia; Childhood; Factor V Leiden

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.3 No.3, September 16, 2013

  ABSTRACT: Thromboembolism is an important complication in children undergoing therapy for ALL as it has the potential to impact adversely on both their survival and quality of life. The incidence of thrombosis in children with ALL varies between 1.1% and 36.7% and the actual mean is 3.2%. The aim of our study is to review the available reported data on the effect of FVL on thrombotic risk in pediatric patients with acute leukemia.